Evidence map›Paper›PMID 38572038›Full record

ArticleIndian journal of dermatology

The Efficacy of Paxman Scalp Cooling System in Preventing Hair Loss in Breast Cancer Patients Receiving Chemotherapy in Western India - Multi-centre Retrospective Cohort Study.

Mangesh Mekha, Ashish Joshi, Vashishth Maniar, Udip Maheshwari, Kshitij Joshi, Pritam Kalaskar, Smit Sheth, Pradip Kendre, Disha Morzaria, Reshma Korgavkar and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Indian journal of dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Mangesh MekhaFrom the Department of Medical Oncology, Mumbai Oncocare Centre, Pune, India.
Ashish JoshiDepartment of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India.
Vashishth ManiarDepartment of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India.
Udip MaheshwariDepartment of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India.
Kshitij JoshiDepartment of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India.
Pritam KalaskarDepartment of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India.
Smit ShethDepartment of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India.
Pradip KendreDepartment of Medical Oncology, Mumbai Oncocare Centre, Mumbai, India.
Disha MorzariaDepartment of Clinical Research, Mumbai Oncocare Centre, Mumbai, India.
Reshma KorgavkarDepartment of Clinical Research, Mumbai Oncocare Centre, Mumbai, India.
Chandrashekhar PetheDepartment of Medical Oncology, Mumbai Oncocare Centre, Nashik, India.
Sonal DhandeDepartment of Medical Oncology, Mumbai Oncocare Centre, Nashik, India.
Bombay Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Chemotherapy-induced alopecia (CIA) is the most common side effect of systemic treatment in breast cancer patients. Scalp cooling gained worldwide acceptance in preventing or mitigating CIA in patients undergoing chemotherapy. The objective of this study was to evaluate the efficacy and safety of the Paxman scalp cooling system (PSCS) in Indian breast cancer patients. Materials and Methods: This is a multi-centre, retrospective-observational study including patients registered from 1 Results: A total of 91 female patients were enrolled in the study, with a median age of 53 years (IQR: 44-62 years). The prevention of alopecia (grade 0 and grade I) was seen in 81%, while more than 50% hair loss (grade 2) was seen in 16.48% after completion of treatment. The univariate analysis results showed that CIA was significantly higher in patients who received anthracyclines (OR: 2.69; 95% CI: 1.04-6.958; Conclusion: PSCS is an effective and well-tolerated treatment modality for preventing CIA among breast cancer patients undergoing chemotherapy.

Indexed as

Anthracyclinesbreast cancerCIAPaxman scalp coolingpost-infusion cooling time

Identifiers

PMID38572038
PMCPMC10986862
OpenAlexW4392250381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.